Eis Eczacibasi Ilac, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.s. · BIST:ECILC
Eis Eczacibasi Ilac, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.s — Eczacıbaşı Pharmaceutical and Industrial Investment — Shareholder Meeting (April 2019)
22 slides from Eis Eczacibasi Ilac, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.s's shareholder meeting presentation, Apr 11, 2019
Slide 1: Ordinary General Assembly Meeting 11 April 2019
EİS ECZACIBAŞI PHARMACEUTICAL AND INDUSTRIAL INVESTMENT CO. ORDINARY GENERAL ASSEMBLY MEETING 11 APRIL 2019
Slide 2: Table of Contents
TABLE OF CONTENTS General Information Activity Information Consolidated Health Real Estate Development Other Future Strategies BIST Indicators
Slide 3: General Information
General Information Shareholding Structure Affiliates and Partnerships Existing Consolidated Structure
Slide 4: Shareholding Structure
SHAREHOLDING STRUCTURE SHARE SHAREHOLDING NAME OF THE SHAREHOLDER AMOUNT RATIO (TL) (%) ECZACIBAŞI HOLDİNG A.Ş. 346,845,460 50.62 ECZACIBAŞI YATIRIM HOLDİNG ORT. A.Ş. 203,294,584 29.67 PUBLIC SHAREHOLDERS (Out-of-Group Shares) 135,119,955 19.71 TOTAL 685,260,000 100.00 BAĞL
Slide 5: Affiliates and Partnerships
AFFILIATES AND PARTNERSHIPS NOMINAL SHAREHOLDING SHAREHOLDING CAPITAL RATIO AMOUNT (TL) (%) (TL) SUBSIDIARIES EİP Eczacıbaşı İlaç Pazarlama A.Ş. 99.9 56,055,120 56,100,000 Eczacıbaşı Gayrimenkul Geliştirme ve Yatırım A.Ş. 99.5 2,487,353 2,500,000 Eczacıbaşı İlaç Ticaret A.Ş. 94.7 47,350 50,000 JOINT
Slide 6: Existing Consolidated Structure
EXISTING CONSOLIDATED STRUCTURE ECILC Health Real Estate Development Other (Partnerships and Activities) • Ecz. İlaç Pazarlama %99.9 • Ecz. Holding %37.3 • Ecz. Gayrimenkul A.Ş. %99.5 • Ecz. İlaç Ticaret %99.8 • Ecz. Dış Ticaret %26,4 • Kanyon Ofis %100 • Tasfiye Hal. Ecz.-Baxter %50 • Vitra Karo %2
Slide 7: Activity Information
Activity Information Consolidated Health Real Estate Development
Slide 8: Consolidated Indicators for 2017-2018
CONSOLIDATED INDICATORS FOR 2017- 2018 (TL MILLION) 2017 2018 ∆ (%) Consolidated Total Assets: 3,831 4,456 16.3 Consolidated Total Equity: 3,481 3,998 14.9
Slide 9: Consolidated Indicators for 2017-2018
CONSOLIDATED INDICATORS FOR 2017- 2018 (TL MILLON) 2017 2018 800 692 700 598 300 600 240 500 200 146 400 300 200 100 100 0 0 CONSOLIDATED CONSOLIDATED REVENUE PROFIT FOR THE PERIOD
Slide 10: 2018 Financial Data on Subsidiaries, Affiliates, and Joint Ventures
2018 FINANCIAL DATA ON SUBSIDIARIES, AFFILIATES, AND JOINT VENTURES Net Income / Direct Operating Loss for the Shareholding Capital Assets Equity Revenue Profit / Loss Period As of 31 December 2018 (*) Ratio (%) (TL) (TL Thousand) (TL Thousand) (TL Thousand) (TL Thousand) (TL Thousand) Subsidiaries
Slide 11: 2018 Consolidated Segment Developments - Health
2018 CONSOLIDATED SEGMENT DEVELOPMENTS - HEALTH - MATERIAL DEVELOPMENTS IN THE SECTOR The calculation method of the fixed Euro rate, on which the drug prices are based in accordance with the drug pricing system of the Ministry of Health, was changed and the new Euro value was increased to TL 3.403
Slide 12: 2018 Segment Developments - Health: EİP
2018 CONSOLIDATED SEGMENT DEVELOPMENTS - HEALTH - DEVELOPMENTS IN ACTIVITIES Eczacıbaşı İlaç Pazarlama (EİP) While the domestic markets where EİP Eczacıbaşı İlaç Pazarlama has operations (Urology, Dermatology, Oncology, Gastroenterology, Respiration, Pain, Anti-Infective, Anesthesia, Nutrition, Su
Slide 13: 2018 Segment Developments - Health: Nuclear Medicine
2018 CONSOLIDATED SEGMENT DEVELOPMENTS - HEALTH - DEVELOPMENTS IN ACTIVITIES Nuclear Medicine Eczacıbaşı - Monrol In 2018, the radiopharmaceutical production activities continued in Romania, Bulgaria and Egypt plants abroad, and in Istanbul, Gebze, Ankara, Izmir, and Adana production plants. Fol
Slide 14: 2018 Segment Developments - Health: Baxter / Shire
2018 CONSOLIDATED SEGMENT DEVELOPMENTS - HEALTH - DEVELOPMENTS IN ACTIVITIES Eczacıbaşı - Baxter / Eczacıbaşı - Shire As a result of Baxter Group's division of Medical Products and Biotechnological Products lines of business in two as Baxter and Baxalta around the world; so as to carry out busines
Slide 15: 2018 Segment Developments - Real Estate: Kanyon
2018 CONSOLIDATED SEGMENT DEVELOPMENTS - REAL ESTATE DEVELOPMENT - KANYON Kanyon, the office block of which is 100% held by EİS and the shopping center of which is 50% held by EİS, continued being a wellness and shopping center with its creative events and new projects. Considering also the incr
Slide 16: 2018 Segment Developments - Real Estate: Ormanada Project
2018 CONSOLIDATED SEGMENT DEVELOPMENTS - REAL ESTATE DEVELOPMENT - ORMANADA PROJECT 50% of the project that was completed at the end of 2014 is held by EIS. The project includes 273 residences and the delivery of about 96% of the residences was performed. In addition; for all the residences in
Slide 17: Future Strategies
Future Strategies
Slide 18: Future Strategies
FUTURE STRATEGIES HEALTH In the healthcare sector, to open new lines of business and to utilize strategic cooperation opportunities, In the field of Biotechnology and Rare Diseases areas, to create local/regional strategic cooperation, In the existing lines of business, to accelerate and deepe
Slide 19: BIST Indicators
BIST Indicators
Slide 20: ECILC - BIST100 (1 January 2018 - 31 March 2019)
ECILC - BIST100 (1 January 2018 - 31 March 2019)
Slide 21: ECILC - BIST100 Performance Summary (5-year)
ECILC - BIST100 PERFORMANCE SUMMARY (5-year)
Slide 22: Thank You
———— THANK YOU ... —/,
Eczacıbaşı Pharmaceutical and Industrial Investment — Shareholder Meeting (April 2019) on 6ix